[Frequency of persistent or transitory serologic negative values in infants with congenital toxoplasmosis. Experience of the Reims Toxoplasmosis Group (1980-1997)].
Chemla
C
C
Villena
I
I
Aubert
D
D
Leroux
B
B
Dupouy
D
D
Pinon
J M
JM
D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood*; D004338:Drug Combinations; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D011739:Pyrimethamine / Q000627:therapeutic use; D015572:Spiramycin / Q000627:therapeutic use; D013413:Sulfadoxine / Q000627:therapeutic use; D014122:Toxoplasma / Q000276:immunology*; D014125:Toxoplasmosis, Congenital / Q000188:drug therapy / Q000276:immunology*
D000913:Antibodies, Protozoan; D004338:Drug Combinations; C001205:fanasil, pyrimethamine drug combination; D015572:Spiramycin; D013413:Sulfadoxine; D011739:Pyrimethamine